Suc­cess­ful list­ing of Al­votech on Nas­daq New York

As stated in Alvotech’s announcement to mark the occasion, the company is focused solely on the development and manufacture of biosimilar medicines for patients which can reduce the cost of health services worldwide.

Another milestone is scheduled for 23 June with the dual listing of Alvotech on Nasdaq First North in Iceland.

Landsbankinn Corporate Finance, Arion Bank and Arctica Finance were among Alvotech’s advisors during the share capital increase preceding listing.

We congratulate the shareholders and employees of Alvotech on listing.